Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both fir...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Case Rep Oncol
Главные авторы: Blasi, Miriam, Kazdal, Daniel, Thomas, Michael, Christopoulos, Petros, Kriegsmann, Mark, Brandt, Regine, Volckmar, Anna-Lena, Kirchner, Martina, Heußel, Claus Peter, Stenzinger, Albrecht, Kuon, Jonas
Формат: Artigo
Язык:Inglês
Опубликовано: S. Karger AG 2021
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077408/
https://ncbi.nlm.nih.gov/pubmed/33976623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513904
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы